207287-79-4

Basic information

• Product Name: 3'-METHOXY-BIPHENYL-4-YLAMINE HYDROCHLORIDE
• Synonyms: CHEMBRDG-BB 4005744;AKOS BAR-0139;3'-METHOXY-BIPHENYL-4-YLAMINE;3'-METHOXY-BIPHENYL-4-YLAMINE HYDROCHLORIDE;3'-METHOXY[1,1'-BIPHENYL]-4-AMINE;3'-METHOXY[1,1'-BIPHENYL]-4-AMINE HYDROCHLORIDE;TIMTEC-BB SBB007493;4-(3-Methoxyphenyl)aniline
• CAS NO: 207287-79-4
• Molecular Formula: C₁₃H₁₃NO
• Molecular Weight: 235.71
• Product Categories: Amines and Anilines
• Mol File: 207287-79-4.mol

Chemical Properties

• Boiling Point: 340.3 °C at 760 mmHg
• Flash Point: 166.3 °C
• Appearance: /
• Density: 1.1 g/cm³
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 4.33±0.10(Predicted)
• CAS DataBase Reference: 3'-METHOXY-BIPHENYL-4-YLAMINE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3'-METHOXY-BIPHENYL-4-YLAMINE HYDROCHLORIDE(207287-79-4)
• EPA Substance Registry System: 3'-METHOXY-BIPHENYL-4-YLAMINE HYDROCHLORIDE(207287-79-4)

Safety Data

• Hazard Codes: Xi
• Statements: 41
• Safety Statements: 26-39
• HazardClass: IRRITANT
• Hazardous Substances Data: 207287-79-4(Hazardous Substances Data)

Usage

Uses

Used in Organic Chemistry:
3'-METHOXY-BIPHENYL-4-YLAMINE HYDROCHLORIDE is used as a chemical intermediate for the synthesis of various organic compounds. Its unique structure allows for the creation of a wide range of derivatives, making it a valuable component in the development of new chemical entities.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 3'-METHOXY-BIPHENYL-4-YLAMINE HYDROCHLORIDE is used as a starting material for the development of potential drug candidates. Its structural features can be exploited to design molecules with specific biological activities, targeting various therapeutic areas such as pain management, inflammation, or even cancer treatment.
Used in Material Science:
3'-METHOXY-BIPHENYL-4-YLAMINE HYDROCHLORIDE can also be employed in the field of material science, where its properties may contribute to the development of novel materials with unique characteristics. For instance, its potential use in the synthesis of organic electronic materials, such as organic light-emitting diodes (OLEDs) or organic solar cells, could lead to advancements in these technologies.

Upstream product

• 10365-98-7 3-methoxyphenylboronic acid 
• 106-40-1 4-bromo-aniline 
• 106-47-8 4-chloro-aniline 
• 100-66-3 methoxybenzene 
• 540-37-4 p-aminoiodobenzene 
• 2845-89-8 1-chloro-3-methoxy-benzene 
• 54609-09-5 4-(2,5-dimethyl-pyrrol-1-yl)-phenol 
• 858364-72-4 N,N-diethyl 4-(2,5-dimethylpyrrol-1-yl)phenyl O-sulfamate 

Downstream Products

• 1266338-76-4 N-(3'-methoxy-3-(N-(phenylsulfonyl)phenylsufonamido)biphenyl-4-yl)acetamide 
• 1360630-31-4 N-(3'-methoxybiphenyl-4-yl)-2-naphthamide 
• 1360630-53-0 N-(3'-methoxybiphenyl-4-yl)naphthalene-2-sulfonamide 
• 1360630-60-9 6-methoxy-N-(3'-methoxybiphenyl-4-yl)naphthalene-2-sulfonamide 
• 1360630-42-7 6-methoxy-N-(3'-methoxybiphenyl-4-yl)-2-naphthamide 
• 1360630-38-1 6-cyano-N-(3'-methoxybiphenyl-4-yl)-2-naphthamide 
• 1360630-33-6 N⁽²⁾-(3'-methoxybiphenyl-4-yl)naphthalene-2,6-dicarboxamide 
• 779341-23-0 cyclohexylcarbamic acid 4'-benzyloxycarbonylaminobiphenyl-3-yl ester 
• 779341-22-9 (3'-hydroxybiphenyl-4-yl)carbamic acid benzyl ester 
• 779341-20-7 4'-amino-1,1'-biphenyl-3-ol 

Relevant articles and documents

Bifunctional Naphtho[2,3- d][1,2,3]triazole-4,9-dione Compounds Exhibit Antitumor Effects in Vitro and in Vivo by Inhibiting Dihydroorotate Dehydrogenase and Inducing Reactive Oxygen Species Production

Human dihydroorotate dehydrogenase (hDHODH) is an attractive target for cancer therapy. Based on its crystal structure, we designed and synthesized a focused compound library containing the structural moiety of 1,4-benzoquinone, which possesses reactive oxygen species (ROS) induction capacity. Compound 3s with a naphtho[2,3-d][1,2,3]triazole-4,9-dione scaffold exhibited inhibitory activity against hDHODH. Further optimization led to compounds 11k and 11l, which inhibited hDHODH activity with IC50 values of 9 and 4.5 nM, respectively. Protein-ligand cocrystal structures clearly depicted hydrogen bond and hydrophobic interactions of 11k and 11l with hDHODH. Compounds 11k and 11l significantly inhibited leukemia cell and solid tumor cell proliferation and induced ROS production, mitochondrial dysfunction, apoptosis, and cell cycle arrest. Nanocrystallization of compound 11l displayed significant in vivo antitumor effects in the Raji xenograft model. Overall, this study provides a novel bifunctional compound 11l with hDHODH inhibition and ROS induction efficacy, which represents a promising anticancer lead worthy of further exploration.

Palladium nanoparticles immobilized on the magnetic few layer graphene support as a highly efficient catalyst for ligand free Suzuki cross coupling and homo coupling reactions

In this study, we prepared a magnetic metal–graphene nanocomposite for the synthesis of substituted biaryls via Suzuki cross coupling and homo coupling reaction of aryl halides. The magnetic few layer graphene composite was synthesized by using one-step electrochemical exfoliation of graphite foil in aqueous iron (II) ammonium sulfate as electrolyte without using of any additive or corrosive media. Then, Fe2O3@FLG composite was used an efficient support for the immobilization and suitable dispersing of palladium nanoparticles. The obtained Fe2O3@FLG@Pd0 nanocomposite was characterized using FT-IR, SEM, TEM, EDS, XRD, VSM and ICP-AES analysis. Very low loading of this catalyst was displayed high activity in the producing substituted biaryls. It simply recovered from the reaction mixture and reused without any pre-activation in six consecutive runs with no loss of its catalytic activity or the observation of any detectable palladium leaching process.

COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS

The present invention relates to compounds of Formula I as defined herein, and salts and solvates thereof. (I) The present invention also relates to pharmaceutical compositions comprising compounds of Formula (I), and to compounds of Formula (I) for use i

Triazole naphthoquinone connected aromatic (heterocyclic) ring derivative

The invention belongs to the field of chemical medicine, particularly relates to a micromolecule capable of resisting malignant tumor, acute leukemia and arthritis, multiple sclerosis and immunological rejection and a preparation and application of the mi

One-Pot Palladium-Catalyzed Cross-Coupling Treble of Borylation, the Suzuki Reaction and Amination

A methodology for a sequential palladium-catalyzed cross-coupling procedure consisting of borylation, the Suzuki reaction and amination has been developed for the assembly of molecules with multi-aryl backbones. The linchpin of this development is the meta-terarylphosphine ligand, Cy*Phine, which has been employed as an air- and moisture-stable precatalyst, Pd(Cy*Phine)2Cl2, to improve the efficiency of one-pot borylation–Suzuki reactions. Additionally, the reactivity of the Pd-Cy*Phine system could be tuned to furnish a one-pot, borylation–Suzuki reaction–amination (BSA) cross-coupling treble. The methodology successfully integrated complementary conditions for three distinctly different and modular reactions. Average yields of 74–94% could be achieved for each segment that cumulatively afforded 50–84% yield over the entire three-step sequence in a single pot. (Figure presented.).

N-heterocyclic carbene coordinated heterogeneous Pd nanoparticles as catalysts for suzuki-miyaura coupling

Palladium nanoparticle (Pd NP) catalysts immobilized in a polymer with an N-heterocyclic carbene (NHC) moiety (PICBNHC-Pd) have been developed, wherein the NHC moiety plays dual roles as a crosslinker and a ligand to activate the Pd NPs. The presence of both Pd NPs and NHC was confirmed by STEM/EDS and SR-MAS NMR analyses, respectively. This PICB-NHC-Pd catalyst showed excellent activity in the Suzuki-Miyaura coupling reaction without leaching of Pd. Excellent results were obtained in gram-scale synthesis, and catalyst recovery/reuse experiments were completed without loss of catalyst activity.

3-Hydroxypyrimidine-2,4-diones as Selective Active Site Inhibitors of HIV Reverse Transcriptase-Associated RNase H: Design, Synthesis, and Biochemical Evaluations

Human immunodeficiency virus (HIV) reverse transcriptase (RT) associated ribonuclease H (RNase H) remains an unvalidated antiviral target. A major challenge of specifically targeting HIV RNase H arises from the general lack of selectivity over RT polymerase (pol) and integrase (IN) strand transfer (ST) inhibitions. We report herein the synthesis and biochemical evaluations of three novel 3-hydroxypyrimidine-2,4-dione (HPD) subtypes carefully designed to achieve selective RNase H inhibition. Biochemical studies showed the two subtypes with an N-1 methyl group (9 and 10) inhibited RNase H in low micromolar range without siginificantly inhibiting RT polymerase, whereas the N-1 unsubstituted subtype 11 inhibited RNase H in submicromolar range and RT polymerase in low micromolar range. Subtype 11 also exhibited substantially reduced inhibition in the HIV-1 INST assay and no significant cytotoxicity in the cell viability assay, suggesting that it may be amenable to further structure-activity relationship (SAR) for identifying RNase H inhibitors with antiviral activity.

Structure-activity relationship study of E6 as a novel necroptosis inducer

Necroptosis inducers represent a promising potential treatment for drug-resistant cancer. We herein describe the structure modification of E6, which was identified recently as a potent and selective necroptosis inducer. The studies described herein demonstrate for the first time that functionalized biphenyl derivatives possess necroptosis inducer activity. Furthermore, these studies have led to the identification of two promising compounds (5h and 5j) that can be used for further optimization studies as well as mechanism of action investigations.

Design, synthesis, X-ray crystallographic analysis, and biological evaluation of thiazole derivatives as potent and selective inhibitors of human dihydroorotate dehydrogenase

Human dihydroorotate dehydrogenase (HsDHODH) is a flavin-dependent mitochondrial enzyme that has been certified as a potential therapeutic target for the treatment of rheumatoid arthritis and other autoimmune diseases. On the basis of lead compound 4, which was previously identified as potential HsDHODH inhibitor, a novel series of thiazole derivatives were designed and synthesized. The X-ray complex structures of the promising analogues 12 and 33 confirmed that these inhibitors bind at the putative ubiquinone binding tunnel and guided us to explore more potent inhibitors, such as compounds 44, 46, and 47 which showed double digit nanomolar activities of 26, 18, and 29 nM, respectively. Moreover, 44 presented considerable anti-inflammation effect in vivo and significantly alleviated foot swelling in a dose-dependent manner, which disclosed that thiazole-scaffold analogues can be developed into the drug candidates for the treatment of rheumatoid arthritis by suppressing the bioactivity of HsDHODH.

Synthesis and evaluation of non-basic inhibitors of urokinase-type plasminogen activator (uPA)

Recent drug discovery programs targeting urokinase plasminogen activator (uPA) have resulted in nonpeptidic inhibitors consisting of amidine or guanidine functional groups attached to aromatic or heteroaromatic scaffolds. There is a general problem of poor oral bioavailability of these charged inhibitors. In this paper, we report the synthesis and evaluation of a series of naphthamide and naphthalene sulfonamides as uPA inhibitors containing non-basic groups as substitute for amidine or guanidine groups.